Articles related to Obstetrics & Gynecology

The modified Mifepristone Risk Evaluation and Mitigation Strategy (REMS) Program eliminates the requirement for in-person dispensing and replaces it with a requirement that pharmacies dispense the drug be certified. Mifepristone, a progestin antagonist, may now be dispensed by or under the supervision of a certified prescriber, or by a certified pharmacy on a prescription issued by a certified prescriber, for medical termination of pregnancy up to 10 weeks gestation (70 days or less since the first day of the last menstrual period).

Healthgrades communicates performance in two ways—through ratings and awards—to assist consumers in evaluating and comparing hospital performance specific to specialist service lines and speciality emphasis areas. Using Medicare inpatient data from the Medicare Provider Analysis and Review (MedPAR) file purchased from the Centers for Medicare and Medicaid Services (CMS) for the years 2019 through 2021, hospitals were evaluated for overall clinical excellence and measure performance. Data on patient outcomes for 31 diseases or treatments were examined for almost all hospitals in the nation. Also, with the fewest occurrences of 14 avoidable patient safety events, hospitals in the top 10% of the country are honored with the Patient Safety Excellence Award, and analyzing data from surveys of the hospital’s own patients to evaluate patient experience across 10 metrics, the top 15% of hospitals receive the Outstanding Patient Experience Award. Finally, each year, Healthgrades recognizes hospitals in the United States that offer the most common gynecologic treatments and where patients are at a decreased risk of complications during their stay for labor and delivery.

If eponyms are avoided, Wernicke encephalopathy, commonly known as Wernicke-Korsakoff syndrome or alcoholic encephalopathy, is a kind of thiamine (vitamin B1) deficiency that is frequently observed in alcoholics. Imaging typically reveals mamillary bodies, dorsomedial thalami, tectal plate, periaqueductal area, and/or the area around the third ventricle as areas of symmetrical enhanced T2/FLAIR signal.

Although research exists on the impact of CNS stimulants used in pregnancy, only a few small studies have looked at atomoxetine and pregnancy outcomes. This large cohort study of 4.2 million pregnancies ending in live births in northern Europe and the US reviewed nearly 1,000 pregnancies exposed to atomoxetine in the first trimester. Compared with non-exposed pregnancies, there was no observed increase in major congenital abnormalities with atomoxetine use in the first trimester.

The literature on chronic pain and stigma was reviewed by a group of academics from Sapienza University of Rome, Italy, who published their findings in the journal Pain and Therapy. Perhaps most unexpectedly, they discovered that stigma surrounding pain persists even in clinical settings, resulting in clinicians’ inadequate evaluations of patients’ pain, doubt about the reality of their suffering, and lower pain ratings. These factors frequently result in inadequate treatment of pain and a propensity to believe that it is solely a psychological disorder.

In this phase 3 double-blind, randomized, 72-week controlled trial of 2,539 adults with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight.